Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/20—Carbocyclic rings
  • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
  • C07C41/01—Preparation of ethers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C67/00—Preparation of carboxylic acid esters
  • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
  • C07C67/29—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/06—Phosphorus compounds without P—C bonds
  • C07F9/08—Esters of oxyacids of phosphorus
  • C07F9/09—Esters of phosphoric acids
  • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
  • C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
  • C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
  • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
  • C07F9/6574—Esters of oxyacids of phosphorus
  • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
  • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
  • G01N21/76—Chemiluminescence; Bioluminescence
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2603/00—Systems containing at least three condensed rings
  • C07C2603/56—Ring systems containing bridged rings
  • C07C2603/58—Ring systems containing bridged rings containing three rings
  • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
  • C07C2603/74—Adamantanes

Definitions

• This invention relates generally to assay methods in which a member of a specific binding pair can be detected and quantified by means of an optically detectable reaction brought about by the enzymolysis of an enzyme-cleavable group in a 1,2-dioxetane molecule.
• the invention relates specifically to the production of 1,2-dioxetanes and their intermediates useable in such assay methods.
• 1,2-Dioxetanes cyclic organic peroxides whose central structure is a four-membered ring containing a pair of contiguous carbon atoms and a pair of contiguous oxygen atoms (a peroxide linkage), are a known, but heretofore seldom utilized, class of compounds. Because of their inherent chemical instability, some 1,2-dioxetanes exhibit chemiluminescent decomposition under certain conditions, e.g., by the action of enzymes, as described in copending, commonly-assigned Bronstein, U.S. patent application Serial No.
• the concentration of the 1,2-dioxetane (and hence the concentration of the substance being assayed, i.e., the species bound to the 1,2-dioxetane member of the specific binding pair) can be determined.
• the appropriate choice of suhstituents on the 1,2-dioxetane ring allows for the adjustment of the chemical stability of the molecule which, in turn, affords a means of controlling the onset of chemiluminescence, thereby enhancing the usefulness of the chemiluminescent behavior of such compounds for practical purposes, e.g., in chemiluminescence immunoassays and DNA probe assays.
• T, R, Y, and Z are defined herein below, from enol ether-type precursors:
• Enol ethers can be prepared by several classical methods, for example, by acid-catalyzed elimination of alcohol from acetals [R.A. Whol, "Synthesis", p. 38 (1974)], by Peterson or Wittig reactions of alkoxymethylene silanes or phosphoranes with aldehydes or ketones in basic media [Magnus, P. et al., Organometallics, 1, 553 (1982)], and by reactions of alkoxyacetic acid dianions with ketones followed by propiolactone formation and elimination of CO 2 [Caron, G., et al., Can. J. Chem., 51, 981 (1973)].
• a polar aprotic solvent such as dimethyl sulfoxide, dimethylformamide, 1,3-dimethyl-2-imidazolidinone, N-methyl-2-pyrrolidinone, and the like, or a mixture of such solvents, results exclusively in O-alkylation.
• the enol ethers thus obtained can be used as convenient intermediates in the synthesis of water-soluble or water compatible 1,2-dioxetanes. Such intermediates can be used to prepare substrates which react with singlet oxygen (generated chemically or photochemically) to yield 1,2-dioxetanes of sufficient stability to be useful in subsequent assay techniques based on chemiluminescent dioxetane decomposition.
• This O-alkylation process is general and therefore extendable to other cycloalkyl aryl ketone substrates, which can be synthesized by the reaction of the appropriate secondary cycloalkyl aldehyde with an aryl Grignard reagent, followed by oxidation of the resulting secondary alcohol with Jones reagent.
• the Grignard reagent is reacted with a secondary cycloalkyl nitrile, followed by acid hydrolysis to form a ketone via an imine salt.
• starting materials and products contain a functional group attached to a secondary carbon atom of the cycloalkyl system, which in the case of fused polycycloalkyl (e.g., adamantyl) systems is flanked on either side by a bridgehead carbon atom. It is, thus, an object of this invention to provide novel synthetic routes to enzyme-cleavable 1,2-dioxetane derivatives.
• Yet another object of this invention is to provide novel compositions of matter, such as trisubstituted enolether phosphates, useful as synthetic precursors of 1,2-dioxetanes which dioxetanes decompose enzymatically in an optically-detectable reaction.
• novel compositions of matter such as trisubstituted enolether phosphates, useful as synthetic precursors of 1,2-dioxetanes which dioxetanes decompose enzymatically in an optically-detectable reaction.
• 1,2-dioxetanes that can be prepared in accordance with the present invention are those having the formula:
• T represents a stabilizing group that prevents the dioxetane compound from decomposing before the bond in the labile ring substituent attached to Y is intentionally cleaved, such as an aryl group, a heteroatom group, or a substituted cycloalkyl group having from 6 to 12 carbon atoms, inclusive, and having one or more alkoxy or alkyl suhstituents containing from 1 to 7 carbon atoms, inclusive, e.g., 4-tertbutyl-1-methyl-cyclohex-1-yl.
• the above groups can be used in any combination to satisfy the valence of the dioxetane ring carbon atom to which they are attached.
• T may be a cycloalkylidene group bonded to the 3-carbon atom of the dioxetane ring through a spiro linkage and having from 5 to 12 carbon atoms, inclusive, which may be further derivatized with one or more suhstituents which can be alkyl or aralkyl groups having from 1 to 7 carbon atoms, inclusive, or a heteroatom group which can be an alkoxy group having from 1 to 12 carbon atoms, inclusive, such as methoxy or ethoxy, e.g., 4-tertbutyl-2,2,6,6-tetramethyl-cyclohexyliden-1-yl.
• the most preferred stabilizing group is a fused polycycloalkylidene group bonded to the 3-carbon atom of the dioxetane ring through a carbon-carbon or a spiro linkage and having two or more fused rings, each having from 3 to 12 carbon atoms, inclusive, e.g., an adamant-2-ylidene or an adamant-2-yl group, which may additionally contain unsaturated bonds or 1,2 fused aromatic rings, or a substituted or unsubstituted alkyl group having from 1 to 12 carbon atoms, inclusive, such as tertiary butyl or 2-cyanoethyl, or an aryl or substituted aryl group such as carboxyphenyl, or a halogen group such as chloro, or a heteroatom group which can be a hydroxyl group or a substituted or unsubstituted alkoxy or aryloxy group having from 1 to 12 carbon atoms, inclusive, such as an eth
• Y represents a light-emitting fluorophore-forming fluorescent chromophore group capable of absorbing energy to form an excited energy state from which it emits optically detectable energy to return to its original energy state. Any carbon position in Y can be attached to the dioxetane ring.
• suitable Y chromophores include: 1) phenylene and phenylene derivatives, e.g., hydroxyphenyl, hydroxybiphenyl, hydroxy-9,10-dihydrophenanthrene;
• naphthalene and naphthalene derivatives e.g., 5-dimethylamino naphthalene-1-sulfonic acid, hydroxy naphthalene, naphthalimides or hydroxy naphthalimides;
• anthracene and anthracene derivatives e.g., 9,10-diphenylanthracene, 9-methylanthracene
• rhodamine and rhodamine derivatives e.g., rhodols, tetraethyl rhodamine, tetraethyl rhodamine, diphenyldimethyl rhodamine, diphenyldiethyl rhodamine, and dinaphthyl rhodamine;
• fluorescein and fluorescein derivatives e.g., 4- or 7-hydroxyfluorescein, 6-iodoacetamido fluorescein, and fluorescein-5-maleimide
• eosin and eosin derivatives e.g., hydroxy eosins, eosin-5-iodoacetamide, and eosin-5-maleimide
• coumarin and coumarin derivatives e.g., 7-dialkylamino-4-methylcoumarin, 4-cyano-7-hydroxy coumarin, and 4-bromomethyl-7-hydroxycoumarin;
• erythrosin and erythrosin derivatives e.g., hydroxy erythrosins, erythrosin-5-iodoacetamide and erythrosin-5-maleimide;
• benzheteroazoles and derivatives e.g., 2-phenylbenzoxazole, hydroxy-2-phenylbenzoxazoles, hydroxy-2-phenylbenzthiazole and hydroxybenzotriazoles;
• pyrene and pyrene derivatives e.g., N-(1-pyrene) iodoacetamide, hydroxypyrenes, and 1-pyrenemethyl iodoacetate:
• stilbene and stilbene derivatives e.g., 6,6'-dibromostilbene and hydroxy stilbenes, hydroxydibenzosuberene;
• nitrobenzoxadiazoles and nitrobenzoxadiazole derivatives e.g., hydroxy nitrobenzoxadiazoles, 4-chloro-7-nitrobenz-2-oxa-1,3-diazol, 2-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) methylaminoacetaldehyde, and 6- (7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoic acid;
• acridine and acridine derivatives e.g., N-methylacridine, N-phenylacridine, hyydroxyacridines, and N-methylhydroxyacridine;
• acidoacridine and acidoacridine derivatives e.g., 9-methylacidoacridine and hydroxy-9-methylacidoacridine;
• carbazole and carbazole derivatives e.g., N-methylcarbazole and hydroxy-N-methylcarbazole
• fluorescent cyanines e.g., DCM (a laser dye), hydroxy cyanines, 1,6-diphenyl-1,3,5-hexatriene,
• carbocyanine and carbocyanine derivatives e.g., phenylcarbocyanine and hydroxy carbocyanines
• pyridinium salts e.g., 4(4-dialkylamino styryl) N-methyl pyridinium salts and hydroxy- substituted pyridinium salts;
• Y chromophores are derivatives of benzene or naphthalene:
• the symbol Z represents hydrogen (in which case the dioxetane can be thermally cleaved via rupture of the oxygen-oxygen bond), a chemically cleavable group such as a hydroxyl group, an alkanoyl or aroyl ester group, or an alkyl or aryl silyloxy group, or an enzyme-cleavable group containing a bond cleavable by an enzyme to yield an electron-rich moiety bonded to chromophore Y, e.g., a bond which, when cleaved, yields an oxygen anion, a sulfur anion, an amine, or a nitrogen anion, and particularly an amido anion such as a sulfonamido anion.
• a chemically cleavable group such as a hydroxyl group, an alkanoyl or aroyl ester group, or an alkyl or aryl silyloxy group
• This moiety initiates the decomposition of the dioxetane into ketone and ester fragments.
• electron-rich moieties include oxygen, sulfur, amine, etc. The most preferred moiety is an oxygen anion.
• suitable enzyme-cleavable groups include enzyme-cleavable alkanoyloxy or aroyloxy groups, e.g., an acetate ester group, or an enzyme-cleavable phosphoryloxy group, oxacarboxylate group, 1-phospho-2,3-diacylgyceride group, D-xyloside group, D-fucoside group, 1-thio-D-glucoside group, adenosine triphosphate analog group, adenosine diphosphate analog group, adenosine monophosphate analog group, adenosine analog group, ⁇ - or ⁇ -D-galactoside group, ⁇ - or ⁇ -D-glucoside group, ⁇ - or ⁇ -D-manno
• R represents a C 1 -C 20 unbranched or branched, substituted or unsubstituted, saturated or unsaturated alkyl group, e.g., methyl, allyl or isobutyl; a heteroaralkyl or aralkyl (including ethylenically unsaturated aralkyl) group, e.g., benzyl or vinylbenzyl; a polynuclear (fused ring) or heteropolynuclear aralkyl group which may be further substituted, e.g., naphthylmethyl or 2-(benzothiazol-2-yl) ethyl; a saturated or unsaturated cycloalkyl group, e.g., cyclohexyl or cyclohexenyl; a N, O, or S heteroatom containing group, e.g., 4-hydroxybutyl, methoxyethyl, or polyalkyleneoxyalkyl;
• One or more of the formula-components T, R, Y or Z can also include a substituent which enhances the water solubility of the 1,2-dioxetane such as a carboxylic acid, sulfonic acid or their salts, or a quaternary amino salt group.
• a substituent which enhances the water solubility of the 1,2-dioxetane such as a carboxylic acid, sulfonic acid or their salts, or a quaternary amino salt group.
• At least one of R and Z, and preferably Z, is an enzyme cleavable group, and preferably an enzyme cleavable phosphate ester or glycosidic acetal group.
• R may be bonded to Y to form a fused ring fluorophore-forming group which is in turn bonded to the 4-carbon atom of the dioxetane through a spiro linkage and which therefore results in an excited lactone fragment upon chemical or enzymatic dioxetane decomposition.
• the required enol ethers are obtained by intramolecular O-alkylation of fused polycycloalkyl aryl ketone enolates by another substituent, e.g., a toluenesulfonyloxyethyl group, in accordance with the methodology presented herein.
• Y may also be further substituted with one or more electron withdrawing groups, e.g., perfluoroalkyl having from 1 to 7 carbon atoms such as trifluoromethyl; alkyl or arylsulfonyl such as methylsulfonyl; halogen such as fluoro or chloro; cyano; nitro; alkoxycarbonyl such as -COOEt; alkanoyl such as -COCH 3 ; amidosulfonyl such as -SO 2 NHAr; or with one or more electron donating groups such as a branched or unbranched alkyl group having from 1 to 7 carbon atoms; an alkoxy or aralkoxy group having from 1 to 30 carbon atoms which may contain fused aromatic or fused heteroaromatic rings which are further substituted with heteroatom containing moieties, e.g., 2-(5-fluoresceinyl)-ethoxy; an aryloxy group having 1 or 2 rings and which may be
• 1,2-dioxetanes and the rate of decomposition of the 1,2-dioxetanes can be varied.
• 1,2-dioxetanes can be attached to various molecules (e.g., proteins or haptens) or immobilizing supports (e.g., polymer membranes); they can also constitute side chain groups of homopolymers or copolymers.
• the method for producing 1,2-dioxetanes according to the present invention comprises the following reaction sequence: wherein R 1 can be independently any of the suhstituents as defined above for R; W is an acid anion such as halide (e.g., chloride); and X and the "R-ylating agent" are as defined below.
• Step 1 which involves the slow attack of an aromatic Grignard reagent on a nitrile, may be run at reflux in several ethereal solvents such as diethyl ether (34o), THF (67o), or ethylene glycol dimethyl ether (85o).
• diethyl ether 34o
• THF 67o
• ethylene glycol dimethyl ether 85o
• the use of THF at reflux provides optimum performance with yields above 90%.
• the use of the analogous organolithium compound to replace the Grignard reagent is possible in the above scheme, however, it is known that THF and organolithium compounds (especially n-butyllithium, the metal-halogen exchange reagent) can be incompatible at higher temperatures. Therefore, one can have recourse to the methodology described in
• Step IV the phenolic ether cleavage with sodium thioethoxide may be accomplished with soft nucleophiles such as with lithium iodide in refluxing pyridine, sodium cyanide in refluxing DMSO, or sodium sulfide in refluxing N-methyl-2-pyrrolidinone are identical in spirit while having other drawbacks from a commercial point of view.
• Steps V, VI and VII, as indicated herein, may be performed separately or in one operation.
• the cyclic phosphorichloridate is utilized not only because of its monofunctionality, chemoselectivity, and enol ethercompatible deprotection mode, but also because, by virtue of pseudo-rotation, it is 10 6 times more reactive than acyclic versions.
• an aromatic hydroxyl group is hindered (e.g., a peri position in a polycyclic, aromatic ring system), or if other suhstituents lower the pKb or nucleophilicity of the enol ether oxyanion, reasonable reaction rates and yields are possible.
• phosphate triester formation with a Lewis base, or with a preformed alkali metal salt can be effected with all of the phosphorochloridates listed over a temperature range of -30o to 50oC.
• the ring cleavage with alkali cyanide in DMF or DMSO should be run in a narrow temperature range between 15o and 30oC. In a one pot or in situ mode this is not important and the range widens to 60oC on the high end.
• phase transfer techniques under catalysis by quaternary ammonium ions or crown ethers to generate an even more reactive "naked" cyanide and thus to utilize organic solvents of higher volatility (e.g., CH 2 Cl 2 ), facilitating work-up.
• organic solvents of higher volatility e.g., CH 2 Cl 2
• the direct use of pure, quaternary ammonium cyanides or sulfinates gives immediate access to phosphate intermediates or products which contain associated gegenions useful in modifying physical properties such as solubility. Such modifications are within the scope of the process parameters disclosed herein.
• Beta-elimination processes brought to bear on the cyanoethyl substituted phosphate diester may occur under the influence of a wide range of bases.
• aqueous ammonium hydroxide can be used in vast excess due to its ease of removal at the end of the process.
• the cleavage can be accomplished over a temperature range of 25o to 100oC.
• provisions must be made to avoid losses of gaseous ammonia, and thus, a high-pressure vessel or bomb is required.
• the preferred temperature range is 35o to 55oC, where the phosphate monoester product is quite stable, and where simple glassware outfitted with wired septa can be used as a closed system.
• Use of alkali metal or quaternary ammonium hydroxides in this step requires close attention to stoichiometry, but as stated above, can provide a variety of mixed gegenion phosphate salts.
• sensitized photooxygenation is a particularly convenient and forgiving process when reactive olefins are used as substrates.
• sensitizing dyes may be used to advantage, with chlorinated hydrocarbons comprising a preferred class of solvents. Reactions are rapid over a temperature range of -78o to 25oC.
• step VI alkyl cleavage with a nucleophilic acidifying anion such as CN- or organic sulfinate ion
• step VII deprotection via a beta-elimination reaction
• the cation, M + , in the salt used in step VI and the cation, M + , in the base used in Step VII can be an alkali metal (e.g., Na + ), ammonium, or a C 1 - C 7 alkyl, aralkyl, or aromatic quaternary ammonium cation, (NR 4 ) + (wherein R 4 can be any or all of an alkyl, e.g., ethyl, aralkyl, e.g., benzyl, or form part of a heterocyclic ring system, e.g., pyridinium), so that the products of steps VII and VIII would be as follows:
• the quaternary ammonium cation can be connected through one of its quaternizing groups to a polymeric backbone, as follows:
• M + can also be a fluorescent onium moiety such as a substituted benzopyrillium or 2-[4-dimethylaminostyryl]-N-methylpyridinium counterion.
• the present invention comprises a process for producing a compound having the formula:
• T , R, R 1 and Y are defined above, by reacting a compound having the formula:
• T is spiro bound at a carbon atom alpha to the carbonyl group, with an alkylating agent (or in more general terms consistent with the definition of R, an "R-ylating agent" selected from the group including R-sulfate, toluenesulfonate ("Tosylate”), methanesulfonate (“mesylate”), trifluoromethanesulfonate (“triflate”), and chloromethyl ethers and trialkyloxonium salts, in a basic, polar, aprotic medium, for example, an alkali metal alkoxide in dimethyl sulfoxide.
• an alkylating agent selected from the group including R-sulfate, toluenesulfonate ("Tosylate"), methanesulfonate (“mesylate”), trifluoromethanesulfonate (“triflate”), and chloromethyl ethers and trialkyloxonium salts, in a basic, polar,
• the invention further provides a process for producing a compound having the formula:
• T, R, and Y are as defined above, comprising reacting a compound having the formula:
• X is an electronegative leaving group such as halogen (e.g., chloro), in the presence of a Lewis base such as a tertiary amine (e.g., triethylamine) dissolved in an aprotic organic solvent, such as an aromatic liquid (e.g., benzene, toluene), and ether (e.g., glyme, diglyme) or a cyclic ether (e.g., tetrahydrofuran (“THF”)).
• a Lewis base such as a tertiary amine (e.g., triethylamine) dissolved in an aprotic organic solvent, such as an aromatic liquid (e.g., benzene, toluene), and ether (e.g., glyme, diglyme) or a cyclic ether (e.g., tetrahydrofuran (“THF”)).
• a Lewis base such as a terti
• the analogous halophosphites i.e., XPO 2 (CH 2 ) 2
• XPO 2 (CH 2 ) 2 can be used with subsequent oxidation and irradiation to form the dioxetane directly.
• the invention provides a process for producing compounds having the formulas:
• R 5 can be independent of any of the suhstituents described above for R, and R 2 and R 3 are each independently cyano, ortho- or para-nitrophenyl, ortho, para- or ortho, ortho'-dinitrophenyl, comprising reacting a compound having the formula:
• X is as defined above, in the presence of a Lewis base such as a tertiary amine (e.g., a trialkylamine) in an aprotic organic solvent such as an aromatic liquid (e.g., benzene or toluene), an ether (e.g., glyme, diglyme) or a cyclic ether (e.g., THF).
• a Lewis base such as a tertiary amine (e.g., a trialkylamine) in an aprotic organic solvent such as an aromatic liquid (e.g., benzene or toluene), an ether (e.g., glyme, diglyme) or a cyclic ether (e.g., THF).
• halophosphates the analogous nor-oxy compounds (i.e., halophosphites) can be used, followed by oxidation at the phosphorous, deprotection and photooxidation to the di
• the oxidation described above is effected photochemically by treating the olefin with singlet oxygen ( 1 P 2 ) in the presence of light.
• 1 O 2 adds across the double bond to form the dioxetane as follows:
• the reaction is preferably carried out at or below 0oC in a halogenated solvent, e.g., methylene chloride.
• 1O 2 can be generated using a photosensitizer.
• photosensitizers polymer-bound Rose Bengal (commercially known as Sensitox I and available from Hydron Laboratories, New Brunswick, N.J.) and methylene blue (a well-known dye and pH indicator) or TPP (see Example 17 below) can be used.
• the present invention also comprises a process for producing a compound of the general structure:
• R, T and Y are as defined above, and Z is a D-sugar molecule linked to Y via a glycosidic linkage, by first reacting a component of the following general structure:
• Y is a phenyl or naphthyl group, with a tetra-O-acetyl-D-hexopyranosyl halide to produce an intermediate of the following general structure:
• glycosides as the ⁇ or ⁇ isomers.
• the use of the acetoxyhalosugars as glycosyl donors in this particular stereoselective mode is illustrative only.
• Y is a fluorophore such as a phenyl or naphthyl moiety
• Z is a sugar linked to Y via an ⁇ or ⁇ glycosidic bond.
• assays examples include immunoassays to detect antibodies or antigens (e.g., hormones such as a or ⁇ -hCG, TSH, LH, etc., cancer-associated antigens such as AFP and CEA) (enzyme-immunoassay); enzyme assays (e.g., alkaline phosphatases and ⁇ - or ⁇ -D-galactosidases); chemical assays to detect cations, e.g., potassium or sodium ions; and nucleotide probe assays to detect, e.g., viruses (e.g., HSVI, HTLV III, hepatitis virus, cytomegalovirus), or bacteria (e.g., E. coli)).
• antibodies or antigens e.g., hormones such as a or ⁇ -hCG, TSH, LH, etc., cancer-associated antigens such as AFP and CEA
• enzyme assays e.g., al
• the enzyme capable of cleaving group Z of the dioxetane is preferably bonded to a substance (i.e, a substance that binds specifically to the detectable substance), e.g., an antigen, antibody, or nucleic acid probe, respectively.
• a substance i.e, a substance that binds specifically to the detectable substance
• Conventional methods e.g., carbodiimide coupling, are used to bond the enzyme to the specific affinity substance; bonding is preferably through an amide linkage.
• assays are performed as follows.
• a sample suspected of containing a detectable substance e.g., antigen
• a buffered solution containing an enzyme bonded to a substance having a specific affinity for the detectable substance e.g., antibody
• the resulting solution is contacted with a solid phase, e.g., antibody-binding beads, to which another substance having the specific affinity, e.g., antibody, is bound.
• excess enzyme which is bound to be substance with specific affinity is then washed away, and a 1,2-dioxetane (substrate) having a group Z that is cleavable by the enzyme portion is added.
• the enzyme cleaves group Z, causing the dioxetane to decompose into ketone and ester moieties; chromophore Y bonded to the ester is thus excited and luminesces.
• Luminescence is detected using, e.g., a cuvette or camera luminometer, as an indication of the presence of the detectable substance in the sample. Luminescence intensity is measured to determine the concentration of the substance.
• an assay for the enzyme involves adding 1,2-dioxetanes to the enzyme-containing sample, and detecting the resulting luminescence as an indication of the presence and the concentration of the enzyme.
• EXAMPLE 5 3-(2'-spiroadamantane)- 4-methoxy-4-(3"-phosphoryloxy)phenyl- 1,2 dioxetane, sodium ammonium salt
• 0.065 g (0.00017 mole) of the enolether phosphate salt, obtained according to Example 4 was dissolved in 25 ml of CHCl 3 .
• a quantity (0.210 g) of methylene blue on silica gel (0.0026 g dye/g SiO 2 ) was added as a sensitizer.
• the tube was placed in a silvered Dewar flask containing a 250 watt, high-pressure sodium lamp inside a water-cooled immersion well.
• a piece of 5 mil Kapton R (Dupont) was placed inside the well as a U.V. filter. Ice water was pumped through the apparatus to maintain the sample temperature below 10oC. A continuous stream of dry oxygen was passed into the reaction vessel through a capillary tube. The gas flow was adjusted so as to just maintain a uniform suspension of the solid-phase sensitizer. After 25 minutes of irradiation time, the U.V. (260 nm) absorption of the starting material disappeared. The light yellow solution was filtered, evaporated, and reconstituted with 10 ml water. The aqueous sample was filtered through a 0.45 micron nylon filter and chromatographed on a reverse phase, C18 preparative HPLC column using a water/acetonitrile gradient. The fractions showing weak U.V. absorption at 277 nm were combined and lyophilized to provide the dioxetane as a white, cotton-like, hygroscopic solid.
• AMPPD Na + NH 4 + salt did not exhibit a melting point. Instead, subliming vaporization occurred between 145° - 150oC. A solid residue remained which partially decomposes but did not melt below 270 oC.
• a portion of the resulting mono pyridinium salt (1 g, 2.3 mmol) was dissolved in 100 ml of CHCl 3 (dried over Al 2 O 3 ). The resulting solution was placed in a large cylindrical tube and treated with 5, 10, 15, 20-tetraphenyl-21H, 23H-porphine (2 mg. in 1 ml of CHCl 3 ). The homogeneous green solution was cooled to 0o and pre-saturated with oxygen gas via a sparger tube.
• the mixture was irradiated under constant O 2 flow in a silvered Dewar flask which also contained a cooled immersion well surrounding a 250 watt sodium vapor lamp which was filtered by a single sheet (5 mil) of DuPont Kapton R polyimide film.
• the temperature in the Dewar remained at 0o - 5oC during a 12 minute irradiation.
• the solvent was removed in vacuo followed by the addition of 100 ml of distilled water containing 500 mg of NaHCO 3 .
• the resulting light pink solution was cooled and filtered through a 0.45 micron Teflon R membrane.
• the resulting aqueous solution of dioxetane was subjected to a CH 3 CN-H 2 O gradient on a polystyrene chromatography column, followed by a second pass with a CH 3 CN - H 2 O gradient.
• the resulting solution which was free of inorganic salts, was lyophilized to produce 800 mg of a granular, faintly yellow, white solid. This solid did not exhibit a melting point. Instead, decomposition to give adamantanone as a subliming vapor occurred between 145o - 150oC. A solid residue remained which partially decomposed, but did not melt below 270oC.
• 1 H N.M.R. (D 2 O) ⁇ .85- ⁇ 1.75 (m, 12H includes 2 doublets at 0.85, 1H and 1.13, 1H); ⁇ 2.15 (s, 1H); ⁇ 2.75 (s, 1H); ⁇ 3.10 (s, 3H); ⁇ 7.10- ⁇ 7.35 (m, 4H).
• the sample was then irradiated with a 250 watt, high pressure sodium lamp at a distance of 3 inches (7.62 cm) from the outer edge of the flask. The disappearance of the band at 260 nm in the UV spectrum was monitored over a 3-hour period. After removal of the sensitizer, the slightly yellow solution was concentrated and chromatographed on a reverse phase, Cl8 preparative HPLC column using 60% acetonitrile/water to 100% acetonitrile gradient. Evaporation of the appropriate fractions provided the dioxetanes as an oil.
• 6-Methoxynaphth-2-yl adamant-2'-yl ketone Magnesium turnings (1.1 g, 0.045 mol) were placed in a flame-dried flask under argon together with a crystal of iodine and 5 ml of dry THF. The suspension was heated to 45oC, while a solution of 2-bromo-6-methoxynapthalene (7.13 g, 0.03 mol) in 25 ml of dry THF was added dropwise. When the exothermic reaction began, the flask was submerged in a water bath at room temperature. After the addition was completed, the reaction mixture was refluxed for 30 minutes.
• EXAMPLE 16 Disodium methoxy[(7-phosphoryloxy-)naphth- 2-yl]methylene adamantane Sodium hydride (50% in mineral oil, 240 mg, 6 mmol) was added under an argon atmosphere to methoxy[ (7-hydroxy)naphth-2-yl]methylene adamantane (1.45 g, 4.5 mmol) dissolved in sieve-dried DMF (15 ml).
• the starting compound is from Edwards, et al., co pending and commonly-assigned U.S. Serial No. 213,672, filed June 30, 1988, Example I. The solution was stirred for 10 min.
• Disodium 3-(2'-spiroadamantane)-4-methoxy-4-(7"- phosphoryloxy)naphth-2"-yl-1,2-dioxetane A solution of disodium methoxy[(7- phosphoryloxy)naphth-2-yl]methylene adamantane (18.8 mg, 0.042 mmol) and 5,10,15,20-tetraphenyl- 21H,23H-porphine (TPP, 20 ⁇ l of a 2% solution in CHCl 3 by weight) in 2% MeOH/CHCl 3 (10 ml) was irradiated with a 250 W, high pressure sodium lamp at 10oC while passing a stream of oxygen through the solution.
• TPP 5,10,15,20-tetraphenyl- 21H,23H-porphine
• the crude product were separated into two fractions by the filtration through a short silica gel column, eluting with 25 - 40% EtOAc in hexanes.
• the less polar mixture (1.05 g) contained mainly the enol ether starting material and a small amount of methoxy(3-acetoxyphenyl)methyleneadamantane.
• the Rf values on TLC (Whatman K5F; 30% EtOAc in hexane) were 0.64 and 0.76 respectively. This mixture could be treated with NaOMe in MeOH to regenerate the starting material, which was recycled.
• EXAMPLE 20 3-(2'-Spiroadamantane)-4-methoxy-4- (3"- ⁇ -D-galactopyranosyloxyphenyl)-1,2-dioxetane
• 75.1 mg (0.17 mmole) of the enol ether galactoside obtained from Example 19 was dissolved in 12 ml of 5% MeOH in CHCl 3 .
• a quantity (0.6 mg) of 5,10,15,20 -tetraphenyl-21H, 23H-porphine (TPP) was added as a sensitizer to form a homogenous violet solution.
• the mixture was saturated with a stream of dry oxygen through a capillary tube and placed in a silvered Dewar flask containing a 250- watt high pressure sodium lamp inside a water-cooled immersion well.
• a piece of 5 mil. Kapton R (DuPont) was placed inside the well as a UV filter. Ice water was pumped through the apparatus to maintain the sample temperature below 10oC.
• the solution was irradiated for 10 minutes under constant O 2 flow, during which time the U.V. absorption at 261nm (CHCl 3 ) of the starting material disappeared and a new peak at 272nm with a shoulder at 278nm appeared.
• the solvent was evaporated at low temperature and the residue was triturated with 30% CH 3 CN in H 2 O.
• the aqueous sample was filtered through a 0.45 micron nylon filter and chromatographed on a reverse phase preparative HPLC column using a water-acetonitrile gradient. After lyophilization the dioxetane was collected as a white, cotton-like powder in good yield. In a melting point capillary tube, the product began to sinter at 97° and proceeded with significant volume loss between 102o and 107o. The powder became moist at 110o, finally producing a clear sticky gum at 118oC.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Immunology (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• Urology & Nephrology (AREA)
• Analytical Chemistry (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• General Physics & Mathematics (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• Genetics & Genomics (AREA)
• Cell Biology (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• Food Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Wood Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Plasma & Fusion (AREA)
• Biophysics (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
• Luminescent Compositions (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Saccharide Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Catalysts (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=22490169

Family Applications (1)

Country Status (13)

Cited By (13)

Families Citing this family (12)

Citations (2)

Family Cites Families (12)

• 1988
  • 1988-07-25 JP JP63185319A patent/JPH0731201B2/ja not_active Expired - Lifetime
  • 1988-12-26 IL IL8879888A patent/IL88798A/en not_active IP Right Cessation
  • 1988-12-28 ZA ZA889659A patent/ZA889659B/xx unknown
  • 1988-12-29 GR GR880100867A patent/GR1000118B/el unknown
  • 1988-12-30 ES ES8804034A patent/ES2012941A6/es not_active Expired - Lifetime
  • 1988-12-30 MX MX1441188A patent/MX14411A/es unknown
• 1989
  • 1989-01-03 AU AU29451/89A patent/AU2945189A/en not_active Abandoned
  • 1989-01-03 DE DE68929060T patent/DE68929060T2/de not_active Expired - Lifetime
  • 1989-01-03 CA CA000587441A patent/CA1341210C/en not_active Expired - Lifetime
  • 1989-01-03 WO PCT/US1989/000016 patent/WO1989006226A1/en not_active Ceased
  • 1989-01-03 JP JP1501800A patent/JP3025280B2/ja not_active Expired - Lifetime
  • 1989-01-03 DE DE68918230T patent/DE68918230T2/de not_active Expired - Lifetime
  • 1989-01-03 EP EP93114829A patent/EP0582317B1/en not_active Expired - Lifetime
  • 1989-01-03 EP EP89901890A patent/EP0368946B1/en not_active Expired - Lifetime
  • 1989-01-05 NZ NZ227525A patent/NZ227525A/en unknown
• 1990
  • 1990-02-14 JP JP2033597A patent/JPH0372489A/ja active Granted
  • 1990-02-14 JP JP2033599A patent/JPH03139298A/ja active Pending
  • 1990-02-14 JP JP2033598A patent/JPH03123791A/ja active Granted
• 1992
  • 1992-11-11 JP JP4324674A patent/JPH0651708B2/ja not_active Expired - Lifetime
• 1993
  • 1993-02-16 JP JP5026654A patent/JPH0733346B2/ja not_active Expired - Lifetime
• 1999
  • 1999-04-20 JP JP11234599A patent/JP3280342B2/ja not_active Expired - Lifetime
  • 1999-04-20 JP JP11112353A patent/JPH11335342A/ja active Pending
• 2000
  • 2000-08-02 US US09/631,300 patent/US6417380B1/en not_active Expired - Fee Related

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events